NPCE logo

NPCE
NeuroPace Inc

331
Mkt Cap
$554.71M
Volume
96,775.00
52W High
$19.60
52W Low
$7.56
PE Ratio
-25.07
NPCE Fundamentals
Price
$16.32
Prev Close
$16.27
Open
$15.91
50D MA
$15.34
Beta
1.18
Avg. Volume
153,367.27
EPS (Annual)
-$0.656
P/B
38.17
Rev/Employee
$478,401.91
$515.01
Loading...
Loading...
News
all
press releases
NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised
NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven by strong RNS System growth.
Zacks·8d ago
News Placeholder
More News
News Placeholder
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of +32.75% and +2.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2026...
Business Wire·9d ago
News Placeholder
BSX Q1 Neuromodulation Sales Rise 15% Y/Y: What Lies Behind the Growth?
Boston Scientific's Neuromodulation unit posts 15% organic sales growth in Q1, fueled by pain management gains, the acquisition of Nalu and momentum in Intracept.
Zacks·13d ago
News Placeholder
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?
NeuroPace (NPCE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·14d ago
News Placeholder
NeuroPace (NPCE) Projected to Post Quarterly Earnings on Tuesday
NeuroPace (NASDAQ:NPCE) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-neuropace-inc-stock...
MarketBeat·16d ago
News Placeholder
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of...
Business Wire·22d ago
News Placeholder
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence...
Business Wire·24d ago
News Placeholder
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the company, MarketBeat...
MarketBeat·25d ago
News Placeholder
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual...
Business Wire·1mo ago
<
1
2
...
>

Latest NPCE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.